

Sloan Leslie  
Form 3  
March 08, 2019

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

OMB  
Number: 3235-0104  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â Sloan Leslie

(Last)

(First)

(Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

03/06/2019

3. Issuer Name **and** Ticker or Trading Symbol  
Aeglea BioTherapeutics, Inc. [AGLE]

4. Relationship of Reporting  
Person(s) to Issuer

5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner

☒ Officer \_\_\_\_ Other  
(give title below) (specify below)

Chief Operating Officer

C/O AEGLEA  
BIOTHERAPEUTICS,  
INC.,Â 901 S. MOPAC  
EXPRESSWAY, SUITE 250

(Street)

AUSTIN,Â TXÂ 78746

(City)

(State)

(Zip)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
☒ Form filed by One Reporting  
Person  
\_\_\_\_ Form filed by More than One  
Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

4. Conversion  
or Exercise  
Price of  
Derivative

5. Ownership  
Form of  
Derivative  
Security:

6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

## Edgar Filing: Sloan Leslie - Form 3

|                                         | Date<br>Exercisable | Expiration<br>Date | Title           | Amount or<br>Number of<br>Shares | Security | Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) |   |
|-----------------------------------------|---------------------|--------------------|-----------------|----------------------------------|----------|------------------------------------------------|---|
| Employee Stock Option<br>(right to buy) | Â <u>(1)</u>        | 10/09/2027         | Common<br>Stock | 55,000                           | \$ 5.975 | D                                              | Â |
| Employee Stock Option<br>(right to buy) | Â <u>(2)</u>        | 02/19/2028         | Common<br>Stock | 80,000                           | \$ 6.31  | D                                              | Â |
| Employee Stock Option<br>(right to buy) | Â <u>(3)</u>        | 02/27/2029         | Common<br>Stock | 72,000                           | \$ 8.36  | D                                              | Â |

## Reporting Owners

| Reporting Owner Name / Address                                                                             | Relationships |           |                           |       |
|------------------------------------------------------------------------------------------------------------|---------------|-----------|---------------------------|-------|
|                                                                                                            | Director      | 10% Owner | Officer                   | Other |
| Sloan Leslie<br>C/O AEGLEA BIOTHERAPEUTICS, INC.<br>901 S. MOPAC EXPRESSWAY, SUITE 250<br>AUSTIN, TX 78746 | Â             | Â         | Â Chief Operating Officer | Â     |

## Signatures

/s/ Charles N. York II, by power of attorney

03/08/2019

                    Signature of Reporting Person

                    Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The stock option vested and became exercisable as to 1/4th of the shares subject to the option on August 28, 2018, and thereafter shall

(1) continue to vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

The stock option vested and became exercisable, and shall continue to vest and become exercisable, in 48 equal monthly installments

(2) beginning on March 20, 2018, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

(3) The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 31, 2019, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.